The Rising Prevalence Of Dry Eye To Boost Dry Eye Syndrome Treatment Market Growth

 

Dry Eye Syndrome Treatment

Dry Eye Syndrome Treatment Market, by Product Type (Cyclosporine, Oral Corticosteroid, Artificial Tears, Omega Supplements, Punctual Bags, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Supermarket/ Hypermarket, Other Stores, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030

The Dry Eye Syndrome Treatment Market is estimated to be valued at US$ XX million in XXX and is expected to exhibit a CAGR of XX% over the forecast period, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

For many people with frequent or mild Dry Eye symptoms, it's ample to regularly utilize nonprescription eye drops, also known artificial tears. If the symptoms are enduring and severe, one might have to visit the physician. Some of the treatments focus on either reducing or reversing the dry eye syndrome.

Competitive Landscape:

Key players involved in the global Dry Eye Syndrome Treatment Market are Sun Pharmaceutical Industries, Inc., Mitotech, Otsuka Pharmaceutical Co., Ltd., AbbVie Inc., Novartis AG, Bausch Health Companies Inc., AFT Pharmaceuticals, Viatris Inc.,  Johnson & Johnson, Inc., Teva Pharmaceutical Industries Ltd., Novaliq GmbH,  I-MED Pharma inc., Santen Pharmaceutical Co., Ltd, SA.

Market Key Drivers:

The rising prevalence of dry eye is expected to augment the growth of the global Dry Eye Syndrome Treatment Market. For instance, as per the American Academy of Ophthalmology (AAO), above the age of 50 years, 1.68 million men and 3.2 million women suffer from dry eye.

The rising approvals and quick launches of the products is projected to propel the growth of global dry eye syndrome treatment market. For instance, Restasis and Cequa are USFDA approved medicines for curing the dry eye symptoms.

Covid-19 Impact Analysis:

The Covid-19 outbreak had adversely affected the growth of global dry eye syndrome treatment market owing to the strict imposition of lockdown and restriction on mobility. The surge in cases had restricted the movement of people from place to place and there was a rise in number of people being addicted to screens of mobile, computer and other electronic gadgets related to work and entertainment. This factor led to the increase in cases of dry eye.

Key Takeaways:

The global Dry Eye Syndrome Treatment Market is anticipated to exhibit a CAGR of XX % during the forecast period owing to rising approvals and quick launches of the products by the key players, innovations in the products. For instance, in January 2021, Eysuvis, a drug approved by U.S. FDA was launched to cure the signs and symptoms of dry eye disease.

Among regions, North America, Europe and Asia Pacific are expected to witness robust growth in global dry eye syndrome treatment market due to rising prevalence of dry eye disease, increasing geriatric population, increasing approvals and launches, investments and collaborations. For instance, in October 2019, Cequa was innovated by Sun Pharmaceutical Industries Ltd. (U.S Based Company) in the region.